Does Eta Protein Differentiate Rheumatoid Arthritis from Psoriatic Arthritis?

Overview

Journal Curr Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2024 Apr 30

PMID 38685775

Authors

Ahmet Kor

Kevser Orhan

Yuksel Maras

Esra Firat Oguz

Mehtap Kalcik Unan

Gamze Dilek

Sukran Erten

Kemal Nas

Affiliations

Soon will be listed here.

Abstract

Aim: The clinical symptoms and laboratory markers of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) can be very similar, so making a differential diagnosis between these two diseases is often difficult. Serological parameters to be used in differential diagnosis can guide the clinician. This study aimed to investigate the usability of 14-3-3η (eta) protein as a biomarker in the differential diagnosis of PsA and RA, and the relationships between eta protein and disease activity scores and joint erosions in PsA and RA.

Methods: 54 PsA patients, 53 RA patients, and 56 healthy individuals were included in this study. The ELISA (Enzyme-Linked ImunoSorbent Assay) kit was used as a quantitative sandwich enzyme immunoassay technique to detect human eta protein levels. Receiver- operating Characteristic (ROC) curves analysis was used to determine the sensitivity and specificity of the eta protein.

Results: Eta protein levels were found to be significantly higher in the RA group than in the PsA [B: -0.341, OR (95% CI): 0.711 (0.556-0.909), p: 0.007] and control [B: -0.225, OR (95% CI): 0.798 (0.641-0.995), p: 0.045] groups. Eta protein median values were significantly higher in patients with joint erosion than in those without [β= 0.151, OR (95% CI): 1.163 (1.003-1.349), p: 0.046].

Conclusion: Eta protein levels are higher in the serum of RA patients than PsA and are associated with joint erosion. Eta protein may be a potential biomarker in the differential diagnosis of RA and PsA. It may represent a possible therapeutic step in the pathophysiological pathways in the development of joint erosion.

References

Ritchlin C, Colbert R, Gladman D . Psoriatic Arthritis. N Engl J Med. 2017; 376(10):957-970. DOI: 10.1056/NEJMra1505557. View

Smolen J, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76(6):960-977. DOI: 10.1136/annrheumdis-2016-210715. View

Knani I, Bouzidi H, Zrour S, Bergaoui N, Hammami M, Kerkeni M . Increased serum concentrations of N-carboxymethyllysine are related to the presence and the severity of rheumatoid arthritis. Ann Clin Biochem. 2017; 55(4):430-436. DOI: 10.1177/0004563217733500. View

Van Hoovels L, Vander Cruyssen B, Sieghart D, Bonroy C, Nagy E, Pullerits R . IgA rheumatoid factor in rheumatoid arthritis. Clin Chem Lab Med. 2022; 60(10):1617-1626. DOI: 10.1515/cclm-2022-0244. View

Smolen J . Rheumatoid arthritis Primer - behind the scenes. Nat Rev Dis Primers. 2020; 6(1):32. DOI: 10.1038/s41572-020-0168-y. View

Smolen J, Landewe R, Bijlsma J, Burmester G, Dougados M, Kerschbaumer A . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79(6):685-699. DOI: 10.1136/annrheumdis-2019-216655. View

Popescu C, Zofota S, Bojinca V, Ionescu R . Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis--cross-sectional study and literature review. J Med Life. 2014; 6(4):376-82. PMC: 3973875. View

Bizzaro N . Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis. Clin Chem Lab Med. 2007; 45(2):150-7. DOI: 10.1515/CCLM.2007.027. View

Burmester G, Pope J . Novel treatment strategies in rheumatoid arthritis. Lancet. 2017; 389(10086):2338-2348. DOI: 10.1016/S0140-6736(17)31491-5. View

10.

Gossec L, Smolen J, Ramiro S, de Wit M, Cutolo M, Dougados M . European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2015; 75(3):499-510. DOI: 10.1136/annrheumdis-2015-208337. View

11.

Ritchlin C, Krueger J . New therapies for psoriasis and psoriatic arthritis. Curr Opin Rheumatol. 2016; 28(3):204-10. PMC: 5812682. DOI: 10.1097/BOR.0000000000000274. View

12.

Cau Y, Valensin D, Mori M, Draghi S, Botta M . Structure, Function, Involvement in Diseases and Targeting of 14-3-3 Proteins: An Update. Curr Med Chem. 2017; 25(1):5-21. DOI: 10.2174/0929867324666170426095015. View

13.

Maksymowych W, van der Heijde D, Allaart C, Landewe R, Boire G, Tak P . 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther. 2014; 16(2):R99. PMC: 4060379. DOI: 10.1186/ar4547. View

14.

Dogan I, Kor A, Guven S, Firat Oguz E, Baser S, Atalar E . 14-3-3 η ETA protein as a potential marker of joint damage in gout. Clin Biochem. 2023; 118:110611. DOI: 10.1016/j.clinbiochem.2023.110611. View

15.

Wang D, Cui Y, Lei H, Cao D, Tang G, Huang H . Diagnostic accuracy of 14-3-3 η protein in rheumatoid arthritis: A meta-analysis. Int J Rheum Dis. 2020; 23(11):1443-1451. PMC: 7756802. DOI: 10.1111/1756-185X.13921. View

16.

Hammam N, Salah S, Kholef E, Moussa E, Marotta A . 14-3-3η Protein in serum and synovial fluid correlates with radiographic damage and progression in a longitudinal evaluation of patients with established rheumatoid arthritis. Mod Rheumatol. 2019; 30(4):664-670. DOI: 10.1080/14397595.2019.1637575. View

17.

Hu T, Liu Y, Tan L, Huang J, Yu J, Wu Y . Value of serum collagen triple helix repeat containing-1(CTHRC1) and 14-3-3η protein compared to anti-CCP antibodies and anti-MCV antibodies in the diagnosis of rheumatoid arthritis. Br J Biomed Sci. 2020; 78(2):67-71. DOI: 10.1080/09674845.2020.1810400. View

18.

Kilani R, Maksymowych W, Aitken A, Boire G, St-Pierre Y, Li Y . Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol. 2007; 34(8):1650-7. View

19.

Cheng-Chung Wei J, Leong P, Liu G . Chaperone/scaffolding/adaptor protein 14-3-3η (eta): A diagnostic marker of rheumatoid arthritis. Int J Rheum Dis. 2020; 23(11):1439-1442. DOI: 10.1111/1756-185X.14004. View

20.

Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham 3rd C . 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9):2569-81. DOI: 10.1002/art.27584. View